|
Age, mean (range)
|
58
|
(44–67)
|
|
Male sex, n (%)
|
9
|
(53)
|
|
BMI, mean (range)
|
27.2
|
(17.5–35.6)
|
|
HCV RNA IE/mL, median (range)
|
2.6 × 106
|
(2.8 × 105 - 16 × 106)
|
|
HCV genotype, n (%)
|
|
1a
|
7
|
(41)
|
|
1b
|
3
|
(18)
|
|
3a
|
5
|
(29)
|
|
1a/1b/1×
|
2
|
(12)
|
|
Descent
|
|
European
|
16
|
(94)
|
|
Middle Eastern
|
1
|
(6)
|
|
Previous IFN treatment, n (%)
|
11
|
(65)
|
|
Psychiatric side effects during IFN treatment, n
|
6
| |
|
Liver cirrhosis, n (%)
|
10
|
(59)
|
|
Child-Pugh A
|
9
| |
|
Child-Pugh B
|
1
| |
|
Current psychiatric morbidity, n (%)
|
6
|
(35)
|
|
Any mood disorder
|
4
|
(24)
|
|
Any substance abuse or dependencea
|
2
|
(12)
|
|
Any anxiety disorder
|
1
|
(6)
|
|
ADHDc
|
2
|
(12)
|
|
Lifetime psychiatric morbidity, n (%)
|
15
|
(88)
|
|
Any mood disorder
|
10
|
(59)
|
|
Any psychotic disorderb
|
1
|
(6)
|
|
Any substance abuse or dependence
|
11
|
(65)
|
|
Any anxiety disorder
|
6
|
(35)
|
|
Any eating disorder
|
2
|
(12)
|
|
ADHDc
|
2
|
(12)
|
|
Psychotropic medication
|
|
Any psychotropic medication
|
8
|
(47)
|
|
Antidepressants
|
3
|
(18)
|
|
Benzodiazepines
|
3
|
(18)
|
|
Benzodiazepine-like agents for sleep
|
3
|
(18)
|
|
Central nervous system stimulants
|
1
|
(6)
|
|
Buprenorphine
|
2
|
(12)
|
